Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash & Equivalents (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Cash & Equivalents data on record, last reported at $984.6 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 26.28% year-over-year to $984.6 million; the TTM value through Dec 2025 reached $984.6 million, up 26.28%, while the annual FY2025 figure was $984.6 million, 26.28% up from the prior year.
  • Cash & Equivalents reached $984.6 million in Q4 2025 per PTCT's latest filing, up from $672.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.5 billion in Q1 2025 and bottomed at $104.4 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $459.4 million, with a median of $244.1 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: plummeted 56.26% in 2021, then skyrocketed 227.39% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $189.7 million in 2021, then skyrocketed by 47.5% to $279.8 million in 2022, then soared by 112.27% to $594.0 million in 2023, then skyrocketed by 31.26% to $779.7 million in 2024, then rose by 26.28% to $984.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $984.6 million in Q4 2025, $672.6 million in Q3 2025, and $1.0 billion in Q2 2025.